the southwest oncology group has evaluated the activity of cis-dichlorodiammineplatinum ( ii ) at a dose of 75 mg/m2 given as an iv bolus injection every 3 weeks to 25 fully and partially evaluable patients with advanced hodgkin 's disease and non-hodgkin 's lymphoma .
C0008838
cis-dichlorodiammineplatinum
C0024305
non-hodgkin 's lymphoma